Related Experiment Video
Updated: Aug 7, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Japanese single-center experience of surgery for chronic thromboembolic pulmonary hypertension
Hitoshi Ogino1, Motomi Ando, Hitoshi Matsuda
1Department of Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan. hogino@hsp.ncvc.go.jp
Insights
Pulmonary endarterectomy surgery for chronic thromboembolic pulmonary hypertension (CTEPH) shows favorable long-term survival and low mortality. Careful surgical consideration is advised for patients with distal disease.
Area of Science:
- Cardiovascular Surgery
- Pulmonary Hypertension Research
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe condition.
- Surgical intervention, specifically pulmonary endarterectomy, is a treatment option for CTEPH.
Purpose of the Study:
- To review the surgical outcomes for patients with CTEPH.
- To evaluate the safety, efficacy, and long-term prognosis of pulmonary endarterectomy.
Main Methods:
- Eighty-eight patients underwent pulmonary endarterectomy between 1995 and 2004.
- The procedure involved intermittent circulatory arrest and hypothermia.
- Lesion location (proximal, subsegmental, peripheral) was categorized.
Main Results:
- Hospital mortality was 8.0%, with pulmonary bleeding and residual hypertension as causes.
- Survivors showed significant reductions in pulmonary artery pressure and vascular resistance (p < 0.0001).
- Actuarial survival was 90.7% at 3 years and 86.4% at 5 years; event-free rates were high.
Conclusions:
- Pulmonary endarterectomy is a safe procedure with low mortality and good long-term survival for CTEPH.
- Distal disease requires careful surgical management, though it does not significantly increase mortality risk.
- Most long-term survivors are weaned from oxygen therapy, indicating significant functional improvement.
Background:
We review the outcome of surgery for chronic thromboembolic pulmonary hypertension (CTEPH).
Methods:
Between 1995 and 2004, 88 patients underwent surgery for CTEPH. Mean pulmonary artery pressure and pulmonary vascular resistance were 46 mm Hg (range, 23 to 70 mm Hg) and 986 dynes.sec(-1).cm(-5) (298 to 2,231 dynes.sec(-1).cm(-5)). The pulmonary artery lesion was proximally located in 51 patients, subsegmental in 34 patients, and peripheral in 3 patients. Pulmonary endarterectomy was performed using cycles of 15-minute intermittent circulatory arrest followed by 10-minute reperfusion at 16 degrees C to 18 degrees C.
Results:
The median durations of circulatory arrest, cardiopulmonary bypass, and surgery were 58, 217, and 355 minutes, respectively. Percutaneous extracorporeal membrane oxygenation was used in 8 patients (9.1%) who had difficulty being weaning from cardiopulmonary bypass. Three recent patients for whom this was performed promptly were weaned and survived. There were 7 hospital deaths (8.0%, including 6 30-day deaths) from pulmonary bleeding in 2 patients, residual pulmonary hypertension in 3, rupture of bulla in 1, and empyema in 1. In the 81 survivors, mean pulmonary artery pressure and pulmonary vascular resistance fell significantly after surgery (p < 0.0001, each case). Age more than 60 years was a risk factor for hospital mortality on multivariate analysis. Although distal pulmonary artery disease including subsegmental and peripheral lesions was not a significant risk factor for mortality, it did influence patient recovery: the frequency of percutaneous extracorporeal membrane oxygenation was higher and hemodynamic improvement less pronounced in patients with distal disease. The actuarial survival rate was 90.7% at 3 years and 86.4% at 5 years. None of the patients have suffered recurrence. The event-free rate was 97.1% at 3 years and 93.5% at 5 years. Of the 68 patients surviving for more than 1 year after surgery, 67.6% were successfully weaned from home oxygen therapy and 13.2% required only occasional use of oxygen.
Conclusions:
Pulmonary endarterectomy can be safely performed with relatively low mortality and favorable prognosis with long-term survival, although it should be performed carefully for patients with distal disease.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism III: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Mitral Stenosis III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...